Prevalence and evaluation of risk factors of anti-retroviral therapy failure among human immunodeficiency virus/acquired immune deficiency syndrome patients in North India.

BACKGROUND The prevalence of anti-retroviral therapy (ART) failure is not uniform in India. In this study we attempted to determine the prevalence and risk factors of treatment failure among patients who were on ART for >1 y. METHODS We conducted an ambispective study from 2017 to 2019 in the All India Institute of Medical Sciences, New Delhi, India. Patients and their past medical records were examined to determine clinical, immunological and virological failure. RESULTS Among 301 enrolled patients, the majority was male (61.8%), with a mean age of 36.98±10.84 y. The prevalence of ART failure in our study was 10.63% (32/301). Clinical, immunological and virological failure rates were 1.66%, 10.63% and 5.65%, respectively. The maximum chance of failure was the tenofovir-lamivudine-nevirapine (33.3%) regimen followed by the stavudine-lamivudine-nevirapine (30.4%) regimen. Among the nucleoside reverse transcriptase inhibitors, a stavudine-based regimen had a significantly greater chance of failure (25.8%) compared with tenofovir (9.6%) and zidovudine (7.9%) regimens (p<0.005). Low baseline CD4 count and development of tuberculosis after ART initiation were significantly (p<0.05) associated with treatment failure in univariate analysis. Patients with a low peak CD4 count (adjusted odds ratio [AOR 4.26 {95% confidence interval 1.83 to 9.88}]) and who developed symptoms after ART initiation (AOR 3.77 [95% CI 1.47 to 9.69]) had significantly higher odds of treatment failure in the multivariate analysis (p<0.001). CONCLUSIONS Early identification of risk factors by regular follow-up and selection of the proper ART regimen can reduce the rate of treatment failure.

[1]  B. Tessema,et al.  Prevalence and associated factors of treatment failure among HIV/AIDS patients on HAART attending University of Gondar Referral Hospital Northwest Ethiopia , 2018, BMC Immunology.

[2]  P. Chand,et al.  A study of profile of patients failing first line NACO recommended ART , 2018, International Journal of Advances in Medicine.

[3]  E. Nibret,et al.  HIV/AIDS Treatment Failure and its Determinant Factors among First Line HAART Patients at Felege-Hiwot Referral Hospital, Bahir Dar, Northwest Ethiopia , 2017 .

[4]  G. A. Alemie,et al.  Predictors of first-line antiretroviral therapy failure amongst HIV-infected adult clients at Woldia Hospital, Northeast Ethiopia , 2017, PloS one.

[5]  S. Shankar,et al.  Predictors of first line antiretroviral therapy failure and burden of second line antiretroviral therapy. , 2017, Medical journal, Armed Forces India.

[6]  U. Chaudhary,et al.  Prevalence of virological failure amongst WHO- defined immunological failure HIV patients on first line of highly active antiretroviral therapy in a tertiary care hospital in Haryana, India - , 2016 .

[7]  M. Ayalew,et al.  First-line antiretroviral treatment failure and associated factors in HIV patients at the University of Gondar Teaching Hospital, Gondar, Northwest Ethiopia , 2016, HIV/AIDS.

[8]  R. Verma,et al.  Profile of HIV Patients on Second Line Antiretroviral Therapy: The Indian Experience , 2015 .

[9]  K. Yirdaw,et al.  Prevalence and Predictors of Immunological Failure among HIV Patients on HAART in Southern Ethiopia , 2015, PloS one.

[10]  T. Bhatnagar,et al.  Predictors of immunological failure and determinants of suboptimal CD4 testing among adults with HIV on first-line antiretroviral therapy in Andhra Pradesh, India, 2008-2011. , 2015, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[11]  P. Venkatesh,et al.  Prevalence of Failure of First-Line Anti-Retroviral Therapy in HIV Patients : A Retrospective Cross-Sectional Study of Six Districts of Andhra Pradesh Over One Decade , 2015 .

[12]  W. Teshome,et al.  Predictors of Immunological Failure of Antiretroviral Therapy among HIV Infected Patients in Ethiopia: A Matched Case-Control Study , 2014, PloS one.

[13]  B. Gelaw,et al.  The effect of incident tuberculosis on immunological response of HIV patients on highly active anti-retroviral therapy at the university of Gondar hospital, northwest Ethiopia: a retrospective follow-up study , 2014, BMC Infectious Diseases.

[14]  C. Laurent,et al.  The vulnerability of men to virologic failure during antiretroviral therapy in a public routine clinic in Burkina Faso , 2014, Journal of the International AIDS Society.

[15]  G. Tessema,et al.  Rate of Immunological Failure and its Predictors among Patients on Highly Active Antiretroviral Therapy at Debremarkos Hospital, Northwest Ethiopia: A Retrospective Follow up Study , 2013 .

[16]  W. Blattner,et al.  Immuno-virologic outcomes and immuno-virologic discordance among adults alive and on anti-retroviral therapy at 12 months in Nigeria , 2013, BMC Infectious Diseases.

[17]  S. Sundar,et al.  Predictive markers of failure of first line anti retroviral treatment in HIV patients in India. , 2013 .

[18]  A. Siika,et al.  Factors Associated with First-Line Antiretroviral Therapy Failure amongst HIV-Infected African Patients: A Case-Control Study , 2012 .

[19]  S. Sundar,et al.  Response to second line antiretroviral therapy in India , 2012, BMC Infectious Diseases.

[20]  J. Pape,et al.  Virologic, clinical and immunologic responses following failure of first-line antiretroviral therapy in Haiti , 2012, Journal of the International AIDS Society.

[21]  C. F. von Reyn,et al.  Disseminated tuberculosis in human immunodeficiency virus infection: ineffective immunity, polyclonal disease and high mortality. , 2011, The International Journal of Tuberculosis and Lung Disease.

[22]  B. Prabhakar,et al.  Immunological failure despite virological suppression in HIV seropositive individuals on antiretroviral therapy , 2011, Indian journal of sexually transmitted diseases and AIDS.

[23]  L. D. Saunders,et al.  Gender differences in antiretroviral treatment outcomes of HIV patients in rural Uganda , 2010, AIDS care.

[24]  S. Mshana,et al.  Prevalence of immunological failure and durability of first line antiretroviral therapy at Bugando Hospital Mwanza, Tanzania , 2010 .

[25]  T. Quinn,et al.  Failure of immunologic criteria to appropriately identify antiretroviral treatment failure in Uganda , 2009, AIDS.

[26]  L. Jeyaseelan,et al.  Predictors of failure of first-line antiretroviral therapy in HIV-infected adults: Indian experience , 2007, AIDS.

[27]  H. Chueh,et al.  Predictors of Antiretroviral Treatment Failure in an Urban HIV Clinic , 2007, Journal of acquired immune deficiency syndromes.

[28]  T. Flanigan,et al.  Reasons for Modification of Generic Highly Active Antiretroviral Therapeutic Regimens Among Patients in Southern India , 2006, Journal of acquired immune deficiency syndromes.